Cme (CME) Cash & Equivalents (2009 - 2026)

Cme (CME) has reported Cash & Equivalents for 18 consecutive years, with $2.1 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 8.22% year-over-year to $2.1 billion; the TTM figure through Jun 2026 stood at $2.1 billion (up 8.22% YoY), while the FY2025 annual figure was $4.4 billion, up 52.71% from the prior year.
• Cash & Equivalents retreated to $2.1 billion in Q2 2026 per CME's latest filing, from $2.4 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $4.4 billion in Q4 2025 and bottomed at $1.4 billion in Q1 2025.
• Historically, Cash & Equivalents has averaged $2.3 billion across 5 years, with a median of $2.1 billion in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 118.46% — and 2023, when it retreated 23.49%.
• Cme's Cash & Equivalents stood at $2.7 billion in 2022, then increased by 7.05% to $2.9 billion in 2023, then declined by 0.67% to $2.9 billion in 2024, then jumped by 52.71% to $4.4 billion in 2025, then tumbled by 51.45% to $2.1 billion in 2026.
• Business Quant data shows CME's Cash & Equivalents at $2.1 billion in Q2 2026, $2.4 billion in Q1 2026, and $4.4 billion in Q4 2025.